Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > phase one

<< Previous

Bullboard Posts

Next >>

Comment by PTBaileyon Mar 31, 2022 3:40pm

124 Views

Post# 34564329

RE:RE:phase one

No one is going to compensate investors for losing B warrants no matter who is at fault for missing targets, and at this point I doubt we will be able to do anything them.

Need to remember this is a penny stock, and as such one of the highest risky things you can invest in. So you shouldn't be putting any money in a penny stock you are not prepared to lose. If you don't what this kind of risk they are far more secure stocks to invest in. But we invest in penny stocks due to the big potential payout if it works.

Anyone who has a low risk tolerace shouldn't be investing in a stock like this.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario